These coincided with the impressive immunotherapy efficacy of STAD with TTN/TP53/MUC16/LRP1B/SYNE1-mutations mentioned in previous studies (Dong et al., 2017; Chen et al., 2019; Li et al., 2020a; Yang et al., 2020). This evidence concerns the gene SYNE1 and gastric adenocarcinoma.